Skip to main content
Midas Edge

BRAINSTORM CELL THERAPEUTICS INC.

For the period ended Dec 31, 2025. Filed Mar 31, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 31, 2026

BCLI$0.97+1.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES

(1)Financial Statements.

The financial statements listed in the Index to Consolidated Financial Statements are filed as part of this report.

(2)Financial Statement Schedules.

All financial statement schedules have been omitted as they are either not required, not applicable, or the information is otherwise included.

(3)Exhibits.
Filed (orIncorporated by Reference Herein
​ ​
2.1Agreement and Plan of Merger, dated as of November 28, 2006, by and between Brainstorm Cell Therapeutics Inc., a Washington corporation, and Brainstorm Cell Therapeutics Inc., a Delaware corporation.Definitive Schedule 14AAppendix A File No. 333-61610November 20, 2006
3.1Certificate of Incorporation of Brainstorm Cell Therapeutics Inc.Definitive Schedule 14AAppendix B File No. 333-61610November 20, 2006
3.2Certificate of Amendment of Certificate of Incorporation of Brainstorm Cell Therapeutics Inc. dated September 15, 2014.Form 8-KExhibit 3.1 File No. 000-54365September 16, 2014
3.3Certificate of Amendment of Certificate of Incorporation of Brainstorm Cell Therapeutics Inc. dated August 31, 2015.Form 8-KExhibit 3.1 File No. 001-366641September 4, 2015
3.4Certificate of Amendment of Certificate of Incorporation of Brainstorm Cell Therapeutics Inc., dated September 16, 2024.​Form 8-KExhibit 3.1 File No. 001-366641September 16, 2024
​​​​​
3.5Certificate of Amendment of Certificate of Incorporation of Brainstorm Cell Therapeutics Inc., dated September 30, 2024.​Form 8-KExhibit 3.1 File No. 001-366641October 1, 2024
​​​​​
3.5ByLaws of Brainstorm Cell Therapeutics Inc.Definitive Schedule 14AAppendix C File No. 333-61610November 20, 2006
3.6Amendment No. 1 to ByLaws of Brainstorm Cell Therapeutics Inc., dated as of March 21, 2007.Form 8-KExhibit 3.1 File No. 333-61610March 27, 2007
​​​​​
3.7Certificate of Amendment to the Brainstorm Cell Therapeutics Inc. Certificate of Incorporation.​Form 8-KExhibit 3.1 File No. 001-36641September 16, 2024
​​​​​​
3.8Certificate of Amendment to the Brainstorm Cell Therapeutics Inc. Certificate of Incorporation.​Form 8-KExhibit 3.1 File No. 001-36641October 1, 2024
​​​​​​
3.9Amendment No. 2 to ByLaws of Brainstorm Cell Therapeutics Inc., dated as of April 20, 2025.​Form 8-KExhibit 3.1 File No. 001-36641April 21, 2025
​​​​​​
4.1Specimen Certificate of Common Stock of Brainstorm Cell Therapeutics Inc.Form 8-KExhibit 4.1 File No. 000-54365September 16, 2014
​​​​​
​​​​​
4.3Form of Common Warrant​Form 8-KExhibit 4.1 File No. 001-36641July 19, 2023
​​​​​​
4.4Common Stock Purchase Warrants (June 2024)Form 8-KExhibit 4.1 File No. 001-36641June 28, 2024
​​​​​​
4.5Pre-Funded Warrant (June 2024)​Form 8-KExhibit 4.2 File No. 001-36641June 28, 2024
​​​​​​
4.6Common Stock Purchase Warrant (Augst 2024)​Form 10-QExhibit 4.1 File No. 001-36641August 14, 2024
​​​​​​
4.7Form of Senior Indenture (including Form of Senior Note)​Form S-3Exhibit 4.2 File No. 333-281827August 28, 2024
​​​​​​
4.8Form of Subordinated Indenture (including Form of Subordinated Note)​Form S-3Exhibit 4.3 File No. 333-281827August 28, 2024
​​​​​​
4.9Common Stock Purchase Warrant (March 2025)​Form 8-KExhibit 4.1 File No. 001-36641March 31, 2025
​​​​​​
4.10Form of Common Stock Purchase Warrant (February 2026)​Form 8-KExhibit 4.1 File No. 001-36641February 13, 2026
​​​​​​
4.10Form of Pre-Funded Warrant (February 2026)​Form 8-KExhibit 4.2 File No. 001-36641February 13, 2026
​​​​​​
4.11Form of Common Stock Purchase Warrant (February 24, 2026)​Form 8-KExhibit 4.1 File No. 001-36641February 27, 2026
​​​​​​
4.12Form of Pre-Funded Warrant (February 24, 2026)​Form 8-KExhibit 4.2 File No. 001-36641February 27, 2026
​​​​​​
10.1Research and License Agreement, dated as of July 8, 2004, by and between the Company and Ramot at Tel Aviv University Ltd.Form 8-KExhibit 10.1 File No. 333-61610July 16, 2004
10.2Research and License Agreement, dated as of March 30, 2006, by and between the Company and Ramot at Tel Aviv University Ltd.Form 8-KExhibit 10.1 File No. 333-61610April 4, 2006
10.3Amendment Agreement, dated as of May 23, 2006, to Research and License Agreement, by and between the Company and Ramot at Tel Aviv University Ltd.Form 8-K/AExhibit 10.1 File No. 333-61610May 30, 2006
10.4Amendment Agreement, dated as of March 31, 2006, among the Company, Ramot at Tel Aviv University Ltd. and certain warrantholders.Form 8-KExhibit 10.2 File No. 333-61610April 4, 2006
10.5Second Amended and Restated Research and License Agreement, dated July 26, 2007, by and between the Company and Ramot at Tel Aviv University Ltd.Form 10-QSBExhibit 10.4 File No. 333-61610August 20, 2007
10.6Second Amended and Restated Registration Rights Agreement, dated August 1, 2007, by and between the Company and Ramot at Tel Aviv University Ltd.Form 10-QSBExhibit 10.5 File No. 333-61610August 20, 2007
10.7Waiver and Release, dated August 1, 2007, executed by Ramot at Tel Aviv University Ltd. in favor of the Company.Form 10-QSBExhibit 10.6 File No. 333-61610August 20, 2007
​​​​​
10.8Letter Agreement, dated December 24, 2009, by and between the Company and Ramot at Tel Aviv University Ltd.Form 8-KExhibit 10.1 File No. 333-61610December 31, 2009
10.9Amendment No. 1, dated December 24, 2009, to the Second Amended and Restated Research and License Agreement dated July 26, 2007 by and between Brainstorm Cell Therapeutics Ltd. and Ramot at Tel Aviv University Ltd.Form 8-KExhibit 10.2 File No. 333-61610December 31, 2009
10.10Assignment Agreement, dated December 20, 2011, by and between the Company and Brainstorm Cell Therapeutics Ltd.Form S-1Exhibit 10.12 File No. 333-179331February 3, 2012
10.11Amendment No. 2, dated April 30, 2014, to the Second Amended and Restated Research and License Agreement dated July 26, 2007 by and between Brainstorm Cell Therapeutics Ltd. and Ramot at Tel Aviv University Ltd.Form 10-KExhibit 10.11 File No. 001-36641March 9, 2016
10.12Amendment No. 3, effective February 18, 2016, to the Second Amended and Restated Research and License Agreement dated July 26, 2007 by and between Brainstorm Cell Therapeutics Ltd. and Ramot at Tel Aviv University Ltd.Form 10-KExhibit 10.12 File No. 001-36641March 9, 2016
10.13Consulting Agreement, dated as of April 30, 2014, by and between Brainstorm Cell Therapeutics Ltd. and Dr. Daniel Offen.Form S-1Exhibit 10.15 File No. 333-179331June 29, 2012
10.14*Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan.Form 8-KExhibit 10.1 File No. 000-54365August 15, 2014
10.15*Amendment No. 1 to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan.Schedule 14AAppendix A File No. 001-36641May 11, 2016
​​​​​
10.16*Amendment No. 2 to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan.Form 8-KExhibit 10.1 File No. 001-36641November 30, 2018
​​​​​
10.17Amendment No. 3 to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan.Schedule 14AAppendix A File No. 001-36641October 1, 2020
​​​​​
10.18*Amendment No. 4 to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan​Form 8-KExhibit 10.5 File No. 001-3664September 16, 2024
​​​​​
10.19*Brainstorm Cell Therapeutics Inc. 2014 Global Share Option Plan.Form 8-KExhibit 10.2 File No. 000-54365August 15, 2014
10.20*Amendment No. 1 to the Brainstorm Cell Therapeutics Inc. 2014 Global Share Option Plan.Schedule 14AAppendix B File No. 001-36641May 11, 2016
10.21*Amendment No. 2 to the Brainstorm Cell Therapeutics Inc. 2014 Global Share Option Plan.8-KExhibit 10.2 File No. 001-36641November 30, 2018
​​​​​
10.22Amendment No. 3 to the Brainstorm Cell Therapeutics Inc. 2014 Global Share Option Plan.​Schedule 14AAppendix B File No. 001-36641October 1, 2020
10.23*Amendment No. 4 to the Brainstorm Cell Therapeutics Inc. 2014 Global Share Option Plan​Form 8-KExhibit 10.10 File No. 001-36641September 16, 2024
​​​​​
10.24*Form of Incentive Stock Option Agreement under the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan.Form 8-KExhibit 10.1 File No. 001-36641November 4, 2014
10.25*Form of Nonstatutory Stock Option Agreement under the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan.Form 8-KExhibit 10.2 File No. 001-36641November 4, 2014
​​​​​
10.26*Form of Restricted Stock Agreement under the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan.Form 8-KExhibit 10.3 File No. 001-36641November 4, 2014
​​​​​
10.27*Form of Option Agreement under the Brainstorm Cell Therapeutics Inc. 2014 Global Share Option Plan.Form 8-KExhibit 10.4 File No. 001-36641November 4, 2014
10.28Subscription Agreement, dated July 2, 2007, by and between the Company and ACCBT Corp.Form 8-KExhibit 10.1 File No. 333-61610July 5, 2007
10.29Amendment to Subscription Agreement, dated as of July 31, 2009, by and between the Company and ACCBT Corp.Form 8-KExhibit 10.1 File No. 333-61610August 24, 2009
10.30Form of Common Stock Purchase Warrant issued by the Company to ACCBT Corp.Form 8-KExhibit 10.2 File No. 333-61610July 5, 2007
10.31Form of Registration Rights Agreement by and between the Company and ACCBT Corp.Form 8-KExhibit 10.3 File No. 333-61610July 5, 2007
10.32Form of Security Holders Agreement, by and between ACCBT Corp. and certain security holders of the Company.Form 8-KExhibit 10.4 File No. 333-61610July 5, 2007
10.33Warrant Amendment Agreement, dated as of May 10, 2012, by and between Brainstorm Cell Therapeutics Inc. and ACCBT Corp.Form 10-QExhibit 10.1 File No. 000-54365May 11, 2012
10.34Amendment of Warrants dated May 19, 2014 by and among Brainstorm Cell Therapeutics Inc., ACCBT Corp. and ACC International Holdings Ltd.Form 10-QExhibit 10.4 File No. 000-54365August 12, 2014
​​​​​
10.352017 Amendment of Warrants and Subscription Agreement dated November 2, 2017 by and among Brainstorm Cell Therapeutics Inc., ACCBT Corp. and ACC International Holdings Ltd.Form 8-KExhibit 10.1 File No. 001-36641November 3, 2017
10.36Clinical Trial Agreement, entered into as of February 17, 2010, among Brainstorm Cell Therapeutics Ltd., Prof. Dimitrios Karousis and Hadasit Medical Research Services and Development Ltd.Form 10-QExhibit 10.1 File No. 000-54365August 15, 2011
​​​​​
10.37Amendment to the Clinical Trial Agreement, entered into as of June 27, 2011, among Brainstorm Cell Therapeutics Ltd., Prof. Dimitrios Karousis and Hadasit Medical Research Services and Development Ltd.Form 10-QExhibit 10.2 File No. 000-54365August 15, 2011
10.38*Employment Agreement dated June 6, 2014 between Brainstorm Cell Therapeutics Ltd. and Uri Yablonka.Form 8-KExhibit 10.1 File No. 000-54365June 9, 2014
10.39*Restricted Stock Award Agreement under the Brainstorm Cell Therapeutics Inc. 2014 Global Share Option Plan, regarding July 26, 2017 grant to Chaim Lebovits.Form 10-QExhibit 10.2 File No. 001-36641October 17, 2017
10.40Form of Securities Purchase Agreement.Form 8-KExhibit 10.1 File No. 000-54365June 13, 2014
10.41Form of Warrant.Form 8-KExhibit 10.2 File No. 000-54365June 13, 2014
​​​​​​
10.42Form of Registration Rights Agreement.Form 8-KExhibit 10.3 File No. 000-54365June 13, 2014
10.43Form of Warrant.Form 8-KExhibit 4.1 File No. 001-36641January 8, 2015
10.44Warrant Exercise Agreement, dated as of January 8, 2015.Form 8-KExhibit 10.2 File No. 001-36641January 8, 2015
10.45Form of Warrant.Form 8-KExhibit 4.1 File No. 001-36641June 7, 2018
10.46Warrant Exercise Agreement.Form 8-KExhibit 10.1 File No. 001-36641June 7, 2018
10.47Leak-Out Agreement.Form 8-KExhibit 10.2 File No. 001-36641June 7, 2018
10.48Share Cap Agreement.Form 10-QExhibit 10.4 File No. 001-36641July 23, 2018
​​​​​
10.49*Employment Agreement dated September 28, 2015 between Brainstorm Cell Therapeutics Inc. and Chaim Lebovits.Form 8-KExhibit 10.1 File No. 001-36641September 28, 2015
10.50*First Amendment to Employment Agreement dated March 7, 2016 between Brainstorm Cell Therapeutics Inc. and Chaim Lebovits.Form 10-KExhibit 10.53 File No. 001-36641March 9, 2016
10.51*Second Amendment to Employment Agreement dated July 26, 2017 between the Company and Chaim Lebovits.Form 10-QExhibit 10.3 File No. 001-36641October 17, 2017
10.52*Employment Agreement dated February 28, 2017 between Brainstorm Cell Therapeutics Inc. and Dr. Ralph Kern, as amended by Amendment No. 1 dated March 3, 2017.Form 8-KExhibit 10.1 File No. 001-36641March 6, 2017
10.53*Brainstorm Cell Therapeutics Inc. Second Amended and Restated Director Compensation Plan.​Form 8-KExhibit 10.1 File No. 001-36641July 10, 2014
​​​​​
10.54*Brainstorm Cell Therapeutics Inc. First Amendment to the Second Amended and Restated Director Compensation Plan.​Form 10-QExhibit 10.2 File No. 001-36641May 14, 2015
​​​​​
10.55*Brainstorm Cell Therapeutics Inc. Second Amendment to the Second Amended and Restated Director Compensation Plan dated February 26, 2017.​Form 10-KExhibit 10.54 File No. 001-36641March 29, 2017
​​​​​
10.56*Brainstorm Cell Therapeutics Inc. Third Amendment to the Second Amended and Restated Director Compensation Plan.​Form 10-QExhibit 10.1 File No. 001-36641October 17, 2017
​​​​​
10.57Brainstorm Cell Therapeutics Inc. Fourth Amendment to the Second Amended and Restated Director Compensation Plan.​Form 10-KExhibit 10.54 File No. 001-36641March 28, 2022
​​​​​
10.58Notice of Award - CLIN2: Partnering Opportunity for Clinical Trial Stage Projects California Institute for Regenerative Medicine, August 25, 2017.​Form 10-KExhibit 10.50 File No. 001-36641March 8, 2018
​​​​​
10.59Distribution Agreement, dated June 11, 2019, by and between Brainstorm Cell Therapeutics Inc. and Raymond James & Associates, Inc.​Form 8-KExhibit 1.1 File No. 001-36641June 11, 2019
​​​​​
10.60Form of Warrant​Form 8-KExhibit 4.1 File No. 001-36641August 2, 2019
​​​​​
10.61Warrant Exercise Agreement​Form 8-KExhibit 10.1 File No. 001-36641August 2, 2019
​​​​​
10.62Form of Warrant Amendment Agreement, dated June 27, 2024 between the Company and the purchaser party thereto​Form 8-KExhibit 10.3 File No. 001 -36641June 28, 2024
​​​​​
10.63*Offer letter, dated April 1, 2020, by and between Brainstorm Cell Therapeutics Inc. and David Setboun​Form 8-KExhibit 10.1 File No. 001-36641April 3, 2020
​​​​​
10.64*Offer letter, dated May 26, 2020, by and between Brainstorm Cell Therapeutics Inc. and Stacy Lindborg​Form 10-KExhibit 10.63 File No. 001-36641February 4, 2021
​​​​​
10.65*Third Amendment to Employment Agreement dated June 23, 2020 between the Company and Chaim Lebovits.​Form 10-QExhibit 10.1 File No. 001-36641August 5, 2020
​​​​​
10.66*Amendment to Employment Agreement dated June 23, 2020 between the Company and Uri Yablonka.​Form 10-QExhibit 10.2 File No. 001-36641August 5, 2020
​​​​​
10.67Distribution Agreement, dated August 9, 2021, by and among Brainstorm Cell Therapeutics, Inc., SVB Leerink LLC and Raymond James & Associates, Inc.​Form S-3Exhibit 1.2 File No. 001-36641August 9, 2021
​​​​​
10.68Amendment No. 1 dated April 2, 2024 to the Distribution Agreement dated August 9, 2021 by and among Brainstorm Cell Therapeutics Inc., Leerink Partners LLC and Raymond James & Associates, Inc.​Form 8-KExhibit 1.1 File No. 001 -36641April 2, 2024
​​​​​
10.69*Amendment No. 2 to Offer Letter Agreement dated September 18, 2022 between Brainstorm Cell Therapeutics Inc. and Dr. Stacy Lindborg​Form 8-KExhibit 10.1 File No. 001-36641September 22, 2022
​​​​​
10.70*Amendment No. 3 to Offer Letter Agreement dated January 3, 2023 between Brainstorm Cell Therapeutics Inc. and Dr. Stacy Lindborg​Form 8-KExhibit 10.1 File No. 001-36641January 4, 2023
​​​​​
10.71*Separation Agreement dated April 16, 2024 between Brainstorm Cell Therapeutics Inc. and Stacy Lindborg​Form 10-QExhibit 10.2 File No. 001-36641August 14, 2024
​​​​​
10.72*Separation Agreement, effective January 20, 2023, between Brainstorm Cell Therapeutics Inc. and Dr. Ralph Kern​Form 8-KExhibit 10.2 File No. 001-36641January 4, 2023
​​​​​
10.73*Employment Agreement dated June 19, 2024 between Brainstorm Cell Therapeutics Inc. and Hartoun Hartounian​Form 10-QExhibit 10.1 File No. 001-36641August 14, 2024
​​​​​
10.74Form of Securities Purchase Agreement​Form 8-KExhibit 10.1 File No. 001-36641July 19, 2023
​​​​​
10.75Form of Securities Purchase Agreement dated June 27, 2024 between Brainstorm Cell Therapeutics Inc. and the purchaser party thereto​Form 8-KExhibit 10.1 File No. 001 -36641June 28, 2024
​​​​​
10.76Placement Agency Agreement, dated as of July 17, 2023 by and between Brainstorm Cell Therapeutics Inc. and the placement agency party thereto​Form 8-KExhibit 10.2 File No. 001-36641July 19, 2023
​​​​​
10.77Placement Agency Agreement, dated as of June 27, 2024 by and between Brainstorm Cell Therapeutics Inc. and the placement agent party thereto​Form 8-KExhibit 10.2 File No. 001 -36641June 28, 2024
​​​​​
10.78*Employment Agreement, dated as of December 23, 2012 by and between Brainstorm Cell Therapeutics Ltd. and Alla Patlis​Form 10-KExhibit 10.69 File No. 001 -36641April 1, 2024
​​​​​
10.79*Amendment No. 1 to Employment Agreement, dated as of March 1, 2015 by and between Brainstorm Cell Therapeutics Ltd. and Alla Patlis​Form 10-KExhibit 10.70 File No. 001 -36641April 1, 2024
​​​​​
10.80*Amendment No. 2 to Employment Agreement, dated as of April 1, 2019 by and between Brainstorm Cell Therapeutics Ltd. and Alla Patlis​Form 10-KExhibit 10.71 File No. 001 -36641April 1, 2024
​​​​​
10.81*Amendment No. 3 to Employment Agreement, dated as of May 1, 2020 by and between Brainstorm Cell Therapeutics Ltd. and Alla Patlis​Form 10-KExhibit 10.72 File No. 001 -36641April 1, 2024
​​​​​
10.82*Amendment No. 4 to Employment Agreement, dated as of August 1, 2022 by and between Brainstorm Cell Therapeutics Ltd. and Alla Patlis​Form 10-KExhibit 10.73 File No. 001 -36641April 1, 2024
​​​​​
10.83*Employment Agreement, dated as of April 16, 2024 by and between Brainstorm Cell Therapeutics Ltd. and Ibrahim B. Dagher​Form 10-KExhibit 10.83March 31, 2025
​​​​​​
10.84Restricted Stock Agreement dated as of June 3, 2024 under the 2014 Global Share Option Plan between Brainstorm Cell Therapeutics Inc. and Chaim Lebovits​Form 10-QExhibit 10.7 File No. 001-36641August 14, 2024
​​​​​
10.85Restricted Stock Agreement dated as of May 2, 2024 under the 2014 Stock Incentive Plan between Brainstorm Cell Therapeutics Inc. and Stacy Lindborg​Form 10-QExhibit 10.8 File No. 001-36641August 14, 2024
​​​​​
10.86Restricted Stock Agreement dated as of April 21, 2024 under the 2014 Global Share Option Plan between Brainstorm Cell Therapeutics Inc. and Alla Patlis​Form 10-QExhibit 10.9 File No. 001-36641August 14, 2024
​​​​​
10.87Restricted Stock Agreement dated as of April 7, 2024 under the 2014 Global Share Option Plan between Brainstorm Cell Therapeutics Inc. and Uri Yablonka​Form 10-QExhibit 10.10 File No. 001-36641August 14, 2024
​​​​​​
10.88Inducement Offer to Exercise Common Stock Purchase Warrants​Form 8-KExhibit 10.1 File No. 001-36641March 31, 2025
​​​​​​
10.89*Amendment No. 5 to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan​Form 8-KExhibit 10.6 File No. 001-3664June 25, 2025
​​​​​​
10.90*Amendment No. 5 to the Brainstorm Cell Therapeutics Inc. 2014 Global Share Option Plan​Form 8-KExhibit 10.12 File No. 001-36641June 25, 2025
​​​​​​
10.91Securities Purchase Agreement, dated November 10, 2025, between the Company and Labrys Fund II, L.P.​Form 8-KExhibit 10.1 File No. 001-36641November 14, 2025
​​​​​​
10.92Promissory Note, issued October 10, 2025, to Labrys Fund II, L.P.​Form 8-KExhibit 10.2 File No. 001-36641November 14, 2025
​​​​​​
10.93Securities Purchase Agreement, dated December 31, 2025, by and between the Company and Vanquish Funding Group Inc.​Form 8-KExhibit 10.1 File No. 001-36641January 9, 2026
​​​​​​
10.94Promissory Note, issued December 31, 2025, to Vanquish Funding Group Inc.​Form 8-KExhibit 10.2 File No. 001-36641January 9, 2026
​​​​​​
10.95Note Purchase Agreement, dated January 5, 2026, by and between the Company and Quick Capital, LLC.​Form 8-KExhibit 10.3 File No. 001-36641January 9, 2026
​​​​​​
10.96Convertible Promissory Note, issued January 5, 2026, to Quick Capital, LLC.​Form 8-KExhibit 10.4 File No. 001-36641January 9, 2026
​​​​​​
10.97Securities Purchase Agreement, dated January 6, 2026, by and between the Company and Auctus Fund, LLC.​Form 8-KExhibit 10.5 File No. 001-36641January 9, 2026
​​​​​​
10.98Convertible Promissory Note, issued January 6, 2026, to Auctus Fund, LLC.​Form 8-KExhibit 10.6 File No. 001-36641January 9, 2026
​​​​​​
10.99Securities Purchase Agreement, dated February 9, 2026​Form 8-KExhibit 10.1 File No. 001-36641February 13, 2026
​​​​​​
10.100Securities Purchase Agreement, dated February 24, 2026​Form 8-KExhibit 10.1 File No. 001-36641February 24, 2026
​​​​​​
10.101*Amendment No. 6 to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan​Form 8-KExhibit 10.8 File No. 001-3664February 27, 2026
​​​​​​
10.102*Amendment No. 6 to the Brainstorm Cell Therapeutics Inc. 2014 Global Share Option Plan​Form 8-KExhibit 10.15 File No. 001-36641February 27, 2026
​​​​​​
​​​​​
21Subsidiaries of the Company.‡​​​
​​​​​
23.1Consent of Brightman Almagor Zohar & Co., a Firm in the Deloitte Global Network.‡​​​
​​​​​
31.1Certification by the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.‡​​​
​​​​​
31.2Certification by the Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.‡​​​
​​​​​
32.1Certification of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.‡‡​​​
​​​​​
32.2Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.‡‡​​​
​​​​​
97.1Brainstorm Cell Therapeutics Inc. Compensation Recovery Policy​Form 10-KExhibit 97.1 File No. 001-36641April 1, 2024
​​​​​
101.SCHInline XBRL Taxonomy Extension Document.‡​​​
101.CALInline XBRL Taxonomy Extension Calculation Linkbase.‡​​​
101.LABInline XBRL Taxonomy Extension Label Linkbase Document.‡​​​
101.PREInline XBRL Taxonomy Extension Presentation Label Linkbase Document.‡​​​
101 DEFInline XBRL Taxonomy Extension Definition Linkbase Document.‡​​​
104Cover Page Interactive Data File (formatted in inline XBRL with applicable taxonomy extension information contained in Exhibits 101)​​​​
*Management contract or compensatory plan or arrangement filed in response to Item 15(a)(3) of Form 10-K.​​​​
‡Filed herewith.​​​​
‡‡Furnished herewith.​​​​
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.